|Bid||1.3800 x 3200|
|Ask||1.4300 x 800|
|Day's Range||1.4000 - 1.4400|
|52 Week Range||1.0000 - 4.2500|
|Beta (3Y Monthly)||-5.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes (T1D) treatment landscape and emerging therapies in New York City on Tuesday, October 8, 2019 from 8:30 am to 10:00 am ET. The event will highlight the current treatment landscape in T1D and unmet need for additional therapies, with a focus on treatment adjuncts to insulin. To register to attend the event, contact Mike Biega, Trout Group: email@example.com or register here.
HIGH POINT, N.C., Sept. 18, 2019 -- vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1.
The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept. 18 poster presentation of clinical data. The company is prepping for the initiation of an adaptive Phase 2/3 study in mild Alzheimer's disease patients with Type 2 diabetes.
Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program HIGH POINT, N.C.,.
HIGH POINT, N.C., Sept. 04, 2019 -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered.
HIGH POINT, N.C., Aug. 06, 2019 -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally.
HIGH POINT, N.C., July 31, 2019 -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019, and provided an update.
vTv Therapeutics Inc. (VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes. In a post hoc analysis of the phase 3 STEADFAST trial, a subgroup of patients with mild Alzheimer’s disease and type 2 diabetes (defined by glycosylated hemoglobin (HbA1c) of greater than 6.5% at any time during the study) who were treated with azeliragon demonstrated a potential benefit in both cognition and function, less brain atrophy and glucose utilization, and decreases in inflammatory biomarkers compared to the same subgroup of patients treated with placebo. ”We are pleased to announce the initiation of this prospective phase 2 proof of concept study whereby we seek to confirm our findings from the post-hoc analyses of the phase 3 STEADFAST trial,” said Steve Holcombe, President and CEO of vTv Therapeutics.
vTv Therapeutics Inc. (VTVT) today announced positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing the liver-selective glucokinase activator TTP399 in adult patients with type 1 diabetes (T1D). In this double-blind, placebo-controlled 12-week trial, the baseline mean HbA1c for the groups treated with TTP399 and placebo was 7.3% and 7.4%, respectively. Patients treated with TTP399 (n=8) showed a statistically significant mean reduction in HbA1c of 0.6% at 12 weeks, while the group treated with placebo (n=11) showed a mean increase in HbA1c of 0.1%, resulting in a mean difference of 0.7% in the TTP399 group relative to the placebo group (p=0.03).
The High Point, North Carolina-based company said it had a loss of 26 cents per share. The biopharmaceutical company posted revenue of $921,000 in the period. In the final minutes of trading on Wednesday, ...
vTv Therapeutics Inc. today reported financial results for the first quarter that ended March 31, 2019, and provided an update on recent achievements and upcoming events.
Biogen's (BIIG) latest clinical trial failure is a testament to the difficulty in developing drugs for Alzheimer's, which is littered with failures in the last ten years. But other neurology fields have ...
vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that its Chief Scientific Officer, Carmen Valcarce, will be presenting at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases held in Lisbon, Portugal, March 26-31, 2019. The presentation will describe the post-hoc analyses of MRI brain volume measures, brain FDG-PET measures of glucose uptake and plasma markers of inflammation in a subgroup of patients with type 2 diabetes, defined as having glycosylated hemoglobin (HbA1c) greater than 6.5%, and mild Alzheimer’s disease in the azeliragon Phase 3 study, STEADFAST.
vTv Therapeutics Inc. (VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering (the “Registered Direct Offering”) of 3,636,364 shares of the Company’s Class A common stock (the “Common Stock”) at a price of $1.65 per share for aggregate gross proceeds of approximately $6.0 million. H.C. Wainwright & Co. is acting as the exclusive placement agent. The Company also entered into a letter agreement (the “Letter Agreement”) with MacAndrews & Forbes Group LLC (“M&F Group”), the Company’s largest shareholder, pursuant to which M&F Group has committed to purchase, at the Company’s option and exercisable on demand during a one-year period after the date of the Letter Agreement, up to 5,454,545 unregistered shares of Common Stock at a fixed price of $1.65 per share for aggregate proceeds of approximately $9.0 million assuming the Company elects to sell the entire amount.